Sechler Marybeth, Cizmic Amber D, Avasarala Sreedevi, Van Scoyk Michelle, Brzezinski Christine, Kelley Nicole, Bikkavilli Rama Kamesh, Winn Robert A
Division of Pulmonary Sciences and Critical Care, University of Colorado, Aurora, CO, USA ; Program in Cancer Biology, University of Colorado, Aurora, CO, USA.
Pharmgenomics Pers Med. 2013 Apr 4;6:25-36. doi: 10.2147/PGPM.S26058. Print 2013.
Targeted therapies for cancer bring the hope of specific treatment, providing high efficacy and in some cases lower toxicity than conventional treatment. Although targeted therapeutics have helped immensely in the treatment of several cancers, like chronic myelogenous leukemia, colon cancer, and breast cancer, the benefit of these agents in the treatment of lung cancer remains limited, in part due to the development of drug resistance. In this review, we discuss the mechanisms of drug resistance and the current strategies used to treat lung cancer. A better understanding of these drug-resistance mechanisms could potentially benefit from the development of a more robust personalized medicine approach for the treatment of lung cancer.
癌症的靶向治疗带来了特异性治疗的希望,与传统治疗相比,具有高效性,在某些情况下毒性更低。尽管靶向治疗在治疗多种癌症(如慢性粒细胞白血病、结肠癌和乳腺癌)方面有巨大帮助,但这些药物在肺癌治疗中的益处仍然有限,部分原因是出现了耐药性。在本综述中,我们讨论了耐药机制以及目前用于治疗肺癌的策略。更好地理解这些耐药机制可能有助于开发更强大的个性化医学方法来治疗肺癌。